Contineum Therapeutics, Inc. Class A Common Stock
CTNM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $50 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $50 | -$0 | $0 |
| % Margin | – | 100% | – | – |
| R&D Expenses | $38 | $28 | $17 | $22 |
| G&A Expenses | $0 | $6 | $0 | $6 |
| SG&A Expenses | $12 | $6 | $5 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $32 | $0 | -$0 |
| Operating Expenses | $51 | $66 | $22 | $29 |
| Operating Income | -$51 | -$16 | -$23 | -$29 |
| % Margin | – | -32.2% | – | – |
| Other Income/Exp. Net | $9 | $39 | -$2 | -$0 |
| Pre-Tax Income | -$42 | $23 | -$24 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$42 | $23 | -$24 | -$29 |
| % Margin | – | 45.4% | – | – |
| EPS | -2.18 | 0.9 | -0.97 | -1.15 |
| % Growth | -342.2% | 192.8% | 15.7% | – |
| EPS Diluted | -2.18 | 0.9 | -0.97 | -1.15 |
| Weighted Avg Shares Out | 19 | 25 | 25 | 25 |
| Weighted Avg Shares Out Dil | 19 | 25 | 25 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $5 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$42 | $24 | -$24 | -$28 |
| % Margin | – | 47.1% | – | – |